Along with GFPT2, various functions of the HBP as well as the O-GlcNAc, which is a post-translational modification using UDP-GlcNAc, the end product of HBP, as a substrate, have also been proposed as targets for cancer treatment [20, 51–53]. The gene discussed is GFPT2; the disease is cancer.